Τόμος 22 (2008) – Τεύχος 2 – Άρθρο 70 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 22 (2008) – Issue 2 – Article 70 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

A΄ Laboratory of Pharmacology, Medical School, Aristotelian University, Thessaloniki, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Todd J. F., Bloom S. R.: Incretins and other peptides in the treatment of diabetes. Diabet. Med. 24: 223-232 (2007)

3. Drucker D.J., Nauck M.A.: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705 (2006)

4. Orskov C., Wettergren A., Holst J.J.: Biological effects and metabolic rates of glucagon like peptide-1 7-36 amide and glucagon like peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658-661 (1993)

5. Marguet D., Baggio L., Kobayashi T., et al.: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA. 97: 6874-6879 (2000)

6. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F.: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA. 84: 3434–3438 (1987)

7. Drucker D.J.: The biology of incretin hormones. Cell. Metab. 3: 153-165 (2006)

8. Nauck M.A., Heimesaat M.M., Behle K., et al.: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. 87: 1239-1246 (2002)

9. Edwards C.M., Todd J.F., Ghatei M.A., Bloom S.R.: Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin. Sci. (Lond.) 95: 719-724 (1998)

10. Scrocchi L.A., Brown T.J., MaClusky N., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2: 1254-1258 (1996)

11. Pratley R.E., Weyer C.: The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44: 929-945 (2001)

12. Nauck M., Stockmann F., Ebert R., Creutzfeldt W.: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52 (1986)

13. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W.: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91: 301-307 (1993)

14. Kolterman O.G., Kim D.D., Shen L., et al.: Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. Health Syst. Pharm. 62: 173-181 (2005)

15. Kendall D.M., Riddle M.C., Rosenstock J., et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091 (2005)

16. Zinman B., Hoogwerf B., Garcia S.G., et al.: Safety and efficacy of exenatide in patients with type 2 diabetes mellitus using thiazolidindiones with or without metformin. Diabetes 55(suppl 1): 28 (abstr 117) (2006)

17. Gedulin B.R., Smith P., Prickett K.S., et al.: Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48: 1380-1385 (2005)

18. Εhren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., Schweizer A.: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89: 2078-2084 (2004)

19. Εhren B., Pacini G., Foley J.E., Schweizer A.: Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28: 1936-1940 (2005)

20. Rosenstock J., Baron M.A., Schweizer A., Mills D., Dejager S.: Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes. Diabetes 5 (suppl 1): 133 (abstr 557) (2006)

21. Aschner P., Kipnes M., Lunceford J., Mickel C., Davies M., Williams-Herman D.: Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes. Diabetes 55(suppl 1): 462 (abstr 1995) (2006)

22. Rosenstock J., Brazg R., Andryuk P.J., McCrary Sisk C., Lu K., Stein P.: Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes. Diabetes 55(suppl 1): 132-133 (abstr 556) (2006)

23. De Meester I., Lambeir A.M., Proost P., Scharpe S.: Dipeptidyl peptidase IV substrates: an update on in vitro peptide hydrolysis by human DPPIV. Adv. Exp. Med. Biol. 524: 3-17 (2003)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr